Page last updated: 2024-08-23

bezafibrate and Glycogen Storage Disease Type II

bezafibrate has been researched along with Glycogen Storage Disease Type II in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beller, M; Giese, AK; Gläser, A; Lukas, J; Pockrandt, AM; Pohlers, S; Rolfs, A; Runge, F; Seemann, S; Sharif, M; Zheng, C	1
Angelini, C; Semplicini, C	1

Reviews

1 review(s) available for bezafibrate and Glycogen Storage Disease Type II

Article	Year
Metabolic myopathies: the challenge of new treatments. Current opinion in pharmacology, 2010, Volume: 10, Issue:3 Topics: Adult; Animals; Bezafibrate; Carnitine O-Palmitoyltransferase; Child; Early Diagnosis; Enzyme Replacement Therapy; Fatty Acids; Glycogen Storage Disease Type II; Glycogen Storage Disease Type V; Humans; Hypolipidemic Agents; Infant; Oxidation-Reduction	2010

Other Studies

1 other study(ies) available for bezafibrate and Glycogen Storage Disease Type II

Article	Year
Enzyme enhancers for the treatment of Fabry and Pompe disease. Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:3 Topics: 1-Deoxynojirimycin; Acetylcysteine; alpha-Galactosidase; alpha-Glucosidases; Ambroxol; Bezafibrate; Enzyme Activators; Fabry Disease; Gene Expression; Glycogen Storage Disease Type II; HEK293 Cells; Humans; Leupeptins; Lysosomes; Pioglitazone; Plasmids; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Recombinant Proteins; Thiazolidinediones; Transfection	2015

Article

Year

Enzyme enhancers for the treatment of Fabry and Pompe disease.

Molecular therapy : the journal of the American Society of Gene Therapy, 2015, Volume: 23, Issue:3

Topics: 1-Deoxynojirimycin; Acetylcysteine; alpha-Galactosidase; alpha-Glucosidases; Ambroxol; Bezafibrate; Enzyme Activators; Fabry Disease; Gene Expression; Glycogen Storage Disease Type II; HEK293 Cells; Humans; Leupeptins; Lysosomes; Pioglitazone; Plasmids; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Stability; Recombinant Proteins; Thiazolidinediones; Transfection

2015